April 30, 2014Open Access

HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention

Key Points

Key points are not available for this paper at this time.

Abstract

Plasma concentrations of tenofovir consistent with daily dosing were highly predictive of protection from HIV acquisition. Most of those who took PrEP seemed to have high and consistent adherence.

Read Full Paperexternally

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Donnell et al. (Wed,) studied this question.

synapsesocial.com/papers/69df575d915fa04953614a74 https://doi.org/https://doi.org/10.1097/qai.0000000000000172

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers2007 · 78 citations
2How Treatment Partners Help: Social Analysis of an African Adherence Support Intervention2011 · 68 citations
3Factors associated with adherence to drug therapy: a population-based study2007 · 60 citations
4Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response2013 · 23 citations
5Improved Horvitz–Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology2009 · 145 citations

Perguntar à IA

Bookmark

View Full Paper